Evolving Concepts in Diabetes Management:

Practical Tools for Integrating GLP-1 Receptor Agonists for Improved Glycemic Control
GLP-1 receptor agonists effectively improve glycemic control with minimal risk of hypoglycemia in patients with type 2 diabetes. Learn more about the benefits of GLP-1 receptor agonists with the RELIEF initiative.
Learn MoreAbout Us
  • GLP-1 receptor agonists are medications that lower blood glucose levels, reduce weight, and lower the risk of adverse cardiovascular and renal outcomes.

  • GLP-1 is a hormone produced by the gut during digestion. As the amount of sugar increases in the bloodstream after a meal, GLP-1 begins increasing the body’s natural production of insulin.

  • GLP-1 receptor agonists only stimulate insulin release in response to rising blood sugar levels after a meal. Unlike insulin injections, GLP-1 receptor agonists have a low risk of hypoglycemia.

4 5

The RELIEF Initiative

The RELIEF initiative aims to provide clinicians and patients with up-to-date information on the use of current and emerging glucagon-like peptide-1 (GLP-1) receptor agonists in the management of type 2 diabetes. By compiling the latest information from clinical trials and treatment guidelines, we aim to provide users with a convenient resource that improves clinical outcomes and quality of life for patients. Through participation in our online and live offerings, our goal is to empower healthcare providers to personalize therapy based on patient-specific factors and improve the standard of care for people with type 2 diabetes. The Clinician Toolkit provides information on treatment guidelines, a summary of important clinical trials, and tips on managing adverse events with GLP-1 receptor agonists. The Patient Toolkit is a handy resource that educates patients about their disease and empowers them to engage in healthcare decisions.

Thank you for visiting our website. Please explore the Clinician Toolkit and Patient Toolkit links below for cutting-edge information on the treatment and management of type 2 diabetes with GLP-1 receptor agonists.